Distal Pancreatectomy with Celiac Axis Resection: Systematic Review and Meta-Analysis.
borderline resectable
pancreatic cancer
vascular reconstruction
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Apr 2021
19 Apr 2021
Historique:
received:
15
03
2021
revised:
15
04
2021
accepted:
15
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Major vascular invasion represents one of the most frequent reasons to consider pancreatic adenocarcinomas unresectable, although in the last decades, demolitive surgeries such as distal pancreatectomy with celiac axis resection (DP-CAR) have become a therapeutical option. A meta-analysis of studies comparing DP-CAR and standard DP in patients with pancreatic adenocarcinoma was conducted. Moreover, a systematic review of studies analyzing oncological, postoperative and survival outcomes of DP-CAR was conducted. Twenty-four articles were selected for the systematic review, whereas eleven were selected for the meta-analysis, for a total of 1077 patients. Survival outcomes between the two groups were similar in terms of 1 year overall survival (OS) (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.34 to 1.31, DP-CAR was not associated with higher mortality compared to standard DP; however, overall morbidity was higher. Celiac axis involvement should no longer be considered a strict contraindication to surgery in patients with locally advanced pancreatic adenocarcinoma. Considering the different baseline tumor characteristics, DP-CAR may need to be compared with palliative therapies instead of standard DP.
Sections du résumé
BACKGROUND
BACKGROUND
Major vascular invasion represents one of the most frequent reasons to consider pancreatic adenocarcinomas unresectable, although in the last decades, demolitive surgeries such as distal pancreatectomy with celiac axis resection (DP-CAR) have become a therapeutical option.
METHODS
METHODS
A meta-analysis of studies comparing DP-CAR and standard DP in patients with pancreatic adenocarcinoma was conducted. Moreover, a systematic review of studies analyzing oncological, postoperative and survival outcomes of DP-CAR was conducted.
RESULTS
RESULTS
Twenty-four articles were selected for the systematic review, whereas eleven were selected for the meta-analysis, for a total of 1077 patients. Survival outcomes between the two groups were similar in terms of 1 year overall survival (OS) (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.34 to 1.31,
CONCLUSIONS
CONCLUSIONS
DP-CAR was not associated with higher mortality compared to standard DP; however, overall morbidity was higher. Celiac axis involvement should no longer be considered a strict contraindication to surgery in patients with locally advanced pancreatic adenocarcinoma. Considering the different baseline tumor characteristics, DP-CAR may need to be compared with palliative therapies instead of standard DP.
Identifiants
pubmed: 33921838
pii: cancers13081967
doi: 10.3390/cancers13081967
pmc: PMC8073522
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
HPB (Oxford). 2016 Oct;18(10):835-842
pubmed: 27506992
Pancreatology. 2018 Jan;18(1):106-113
pubmed: 29153701
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Ann Surg Oncol. 2019 Mar;26(3):772-781
pubmed: 30610560
J Am Coll Surg. 2014 Mar;218(3):401-11
pubmed: 24484730
J Gastrointest Surg. 2016 Feb;20(2):300-6
pubmed: 26525205
J Gastrointest Surg. 2018 Oct;22(10):1804-1810
pubmed: 30105677
Surgery. 2012 Jan;151(1):61-9
pubmed: 22088810
Ann Surg. 2007 Jul;246(1):46-51
pubmed: 17592290
Cancer. 1953 Jul;6(4):704-7
pubmed: 13059764
Ann Surg. 1999 May;229(5):693-8; discussion 698-700
pubmed: 10235528
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):353-363
pubmed: 28823364
J Hepatobiliary Pancreat Sci. 2012 Mar;19(2):141-7
pubmed: 22076669
Ann Surg Treat Res. 2015 Oct;89(4):167-75
pubmed: 26446424
Surg Oncol. 2017 Mar;26(1):53-62
pubmed: 28317585
Eur J Surg Oncol. 2020 Jun;46(6):1189-1191
pubmed: 32389524
J Gastrointest Surg. 2020 Jul;24(7):1605-1611
pubmed: 31325134
Medicine (Baltimore). 2016 Mar;95(10):e3061
pubmed: 26962836
Hepatogastroenterology. 2013 Jan-Feb;60(121):187-90
pubmed: 22784943
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
Ann Surg Oncol. 2016 Jun;23(6):2028-37
pubmed: 26893222
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061
pubmed: 28784865
Cancer. 2011 May 15;117(10):2044-9
pubmed: 21523715
Br J Surg. 1996 Aug;83(8):1065-70
pubmed: 8869304
Int J Surg. 2018 Jul;55:103-109
pubmed: 29803770
J Hepatobiliary Pancreat Surg. 2000;7(2):183-7
pubmed: 10982611
HPB (Oxford). 2015 Sep;17(9):777-84
pubmed: 26201994
Cancers (Basel). 2020 Jul 20;12(7):
pubmed: 32698500
Ann Surg Oncol. 2021 Feb;28(2):1106-1108
pubmed: 32588265
Langenbecks Arch Surg. 2020 Nov;405(7):903-919
pubmed: 32894339
Surgeon. 2020 Oct 3;:
pubmed: 33023848
Ann Surg Oncol. 2016 Oct;23(11):3757-3764
pubmed: 27328946
J Natl Compr Canc Netw. 2020 Jul;18(7):806-815
pubmed: 32634771
Ann Surg Oncol. 2020 Oct 13;:
pubmed: 33051739
World J Surg. 2016 Sep;40(9):2245-53
pubmed: 27198999
Langenbecks Arch Surg. 2003 Apr;388(2):101-6
pubmed: 12684805
Eur J Surg Oncol. 2014 Apr;40(4):371-8
pubmed: 24560302
Abdom Radiol (NY). 2018 Feb;43(2):301-313
pubmed: 29198002
J Gastrointest Surg. 2008 Dec;12(12):2183-90
pubmed: 18683009
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Surgery. 2015 Apr;157(4):811-7
pubmed: 25532436
J Cancer Res Ther. 2018 Dec;14(Supplement):S1019-S1023
pubmed: 30539839
Langenbecks Arch Surg. 2020 Aug;405(5):635-645
pubmed: 32683485
J Gastrointest Surg. 2007 Jun;11(6):743-9
pubmed: 17417712
Surg Endosc. 2011 May;25(5):1642-51
pubmed: 21184115
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg. 2011 Dec;254(6):882-93
pubmed: 22064622
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
pubmed: 11307091
Ann Surg. 2015 Jan;261(1):12-7
pubmed: 25599322
Surg Today. 2003;33(11):873-8
pubmed: 14605963
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Surgery. 2013 Mar;153(3):365-72
pubmed: 23046987
J Gastrointest Surg. 2012 Jun;16(6):1152-9
pubmed: 22399269
Ann Surg Oncol. 2016 Dec;23(Suppl 5):969-975
pubmed: 27495282
J Gastrointest Surg. 2005 Apr;9(4):503-7
pubmed: 15797231
Med Sci Monit. 2014 Jan 02;20:1-5
pubmed: 24382572
World J Gastroenterol. 2010 Feb 21;16(7):818-31
pubmed: 20143460
World J Surg. 2017 Jan;41(1):258-266
pubmed: 27473130
Ann Surg Oncol. 2010 May;17(5):1359-66
pubmed: 20198445
Anticancer Res. 2020 Jan;40(1):387-392
pubmed: 31892591
Langenbecks Arch Surg. 2019 Jun;404(4):451-458
pubmed: 30868241
World J Surg Oncol. 2019 Jul 17;17(1):124
pubmed: 31315628
J Natl Compr Canc Netw. 2019 May 1;17(5.5):603-605
pubmed: 31117041
J Hepatobiliary Pancreat Surg. 2009;16(2):229-33
pubmed: 19224117
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
World J Surg. 2011 Nov;35(11):2535-42
pubmed: 21901326
BMC Surg. 2017 Nov 23;17(1):109
pubmed: 29169392
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005
Cancer Treat Rev. 2016 Jan;42:56-72
pubmed: 26643552